These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 15049898

  • 1. Preferential HER-2/neu overexpression and/or amplification in aggressive histological subtypes of invasive breast cancer.
    Varga Z, Zhao J, Ohlschlegel C, Odermatt B, Heitz PU.
    Histopathology; 2004 Apr; 44(4):332-8. PubMed ID: 15049898
    [Abstract] [Full Text] [Related]

  • 2. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
    Latta EK, Tjan S, Parkes RK, O'Malley FP.
    Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
    [Abstract] [Full Text] [Related]

  • 3. Histological tumor grade correlates with HER2/c-erB-2 status in invasive breast cancer: a comparative analysis between immunohistochemical (CB11 clone and Herceptest), FISH and differential PCR procedures.
    López-Guerrero JA, Navarro S, Noguera R, Almenar S, Pellin A, Vázquez C, Llombart-Bosch A.
    Arkh Patol; 2003 Dec; 65(1):50-5. PubMed ID: 12669615
    [Abstract] [Full Text] [Related]

  • 4. HER2 status in breast cancer determined by IHC and FISH: comparison of the results.
    Mrozkowiak A, Olszewski WP, Piaścik A, Olszewski WT.
    Pol J Pathol; 2004 Dec; 55(4):165-71. PubMed ID: 15757204
    [Abstract] [Full Text] [Related]

  • 5. Detection of human epidermal growth factor receptor 2 protein and gene in fine needle aspiration cytology specimens and tissue sections from invasive breast cancer: can cytology specimens take the place of tissue sections?
    Sumiyoshi K, Shibayama Y, Akashi S, Nohara T, Iwamoto M, Kobayashi T, Nishimura H, Yoshinaka R, Harada T, Tanigawa N.
    Oncol Rep; 2006 Apr; 15(4):803-8. PubMed ID: 16525662
    [Abstract] [Full Text] [Related]

  • 6. Algorithm for the diagnosis of HER-2/neu status in breast-infiltrating carcinomas.
    Falo C, Moreno A, Lloveras B, Figueras A, Varela M, Escobedo A.
    Am J Clin Oncol; 2003 Oct; 26(5):465-70. PubMed ID: 14528071
    [Abstract] [Full Text] [Related]

  • 7. Intratumoral heterogeneity of HER2/neu in breast cancer--a rare event.
    Hanna W, Nofech-Mozes S, Kahn HJ.
    Breast J; 2007 Oct; 13(2):122-9. PubMed ID: 17319852
    [Abstract] [Full Text] [Related]

  • 8. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization.
    Cho EY, Choi YL, Han JJ, Kim KM, Oh YL.
    Pathol Int; 2008 Jan; 58(1):17-25. PubMed ID: 18067636
    [Abstract] [Full Text] [Related]

  • 9. Protein expression and molecular analysis of c-myc gene in primary breast carcinomas using immunohistochemistry and differential polymerase chain reaction.
    Naidu R, Wahab NA, Yadav M, Kutty MK.
    Int J Mol Med; 2002 Feb; 9(2):189-96. PubMed ID: 11786932
    [Abstract] [Full Text] [Related]

  • 10. Overexpression/amplification of HER-2/neu is uncommon in invasive carcinoma of the uterine cervix.
    Rosty C, Couturier J, Vincent-Salomon A, Genin P, Fréneaux P, Sigal-Zafrani B, Sastre-Garau X.
    Int J Gynecol Pathol; 2004 Jan; 23(1):13-7. PubMed ID: 14668544
    [Abstract] [Full Text] [Related]

  • 11. Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization.
    Santin AD, Bellone S, Van Stedum S, Bushen W, De Las Casas LE, Korourian S, Tian E, Roman JJ, Burnett A, Pecorelli S.
    Gynecol Oncol; 2005 Jul; 98(1):24-30. PubMed ID: 15894362
    [Abstract] [Full Text] [Related]

  • 12. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.
    Simonetti S, Russo R, Ciancia G, Altieri V, De Rosa G, Insabato L.
    Int J Surg Pathol; 2009 Jun; 17(3):198-205. PubMed ID: 19443884
    [Abstract] [Full Text] [Related]

  • 13. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing.
    Schmidt M, Lewark B, Kohlschmidt N, Glawatz C, Steiner E, Tanner B, Pilch H, Weikel W, Kölbl H, Lehr HA.
    Breast Cancer Res; 2005 Jun; 7(2):R256-66. PubMed ID: 15743506
    [Abstract] [Full Text] [Related]

  • 14. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
    Kammori M, Kurabayashi R, Kashio M, Sakamoto A, Yoshimoto M, Amano S, Kaminishi M, Yamada T, Takubo K.
    Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
    [Abstract] [Full Text] [Related]

  • 15. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
    Wu Y, Soslow RA, Marshall DS, Leitao M, Chen B.
    Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
    [Abstract] [Full Text] [Related]

  • 16. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP, Tsoli E, Fouskakis D, Yiotis J, Koullias GJ, Giannopoulos D, Papalambros E, Nikiteas NI, Spiliopoulou CA, Patsouris E, Asimacopoulos P, Gorgoulis VG.
    Anticancer Res; 2004 Dec; 24(3b):2061-8. PubMed ID: 15274401
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of the clinical significance of HER2 amplification by chromogenic in situ hybridisation in patients with primary breast cancer.
    Dandachi N, Dietze O, Hauser-Kronberger C.
    Anticancer Res; 2004 Dec; 24(4):2401-6. PubMed ID: 15330190
    [Abstract] [Full Text] [Related]

  • 18. Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland.
    Cornolti G, Ungari M, Morassi ML, Facchetti F, Rossi E, Lombardi D, Nicolai P.
    Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1031-6. PubMed ID: 17938328
    [Abstract] [Full Text] [Related]

  • 19. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.
    Salido M, Tusquets I, Corominas JM, Suarez M, Espinet B, Corzo C, Bellet M, Fabregat X, Serrano S, Solé F.
    Breast Cancer Res; 2005 Oct; 7(2):R267-73. PubMed ID: 15743507
    [Abstract] [Full Text] [Related]

  • 20. Effect of high copy number of HER2 associated with polysomy 17 on HER2 protein expression in invasive breast carcinoma.
    Shah SS, Wang Y, Tull J, Zhang S.
    Diagn Mol Pathol; 2009 Mar; 18(1):30-3. PubMed ID: 19214111
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.